Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment.
Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment.
Data
2021
Autores
Meirelles, Isandra de Oliveira
Magliano, Carlos Alberto da Silva
Journal Title
Journal ISSN
Volume Title
Publisher
Patient Prefer Adherence
Resumo
Introduction The different alternatives for non-small-cell lung cancer (NSCLC) treatment can increase survival but cause important adverse events. Therefore, patients’ preference can play a critical role in decision-making. Among stated preference methods, discrete choice experiment (DCE) is the most applied in health care to elicit preferences. This research aims to elicit patients’ preference evaluating the trade-off between the risks (adverse events) and benefits (survival) of systemic treatments, from the perspective of Brazilian patients with locally advanced, metastatic or recurrent NSCLC. Methods A DCE was performed following the steps of attributes selection; construction of tasks and respondents’ preference elicitation. Patients chose between 2 hypothetical treatments described by the attributes tiredness, hair loss, skin rash, hospitalization, administration mode and survival. A paper-and-pencil survey method was used to elicit the answers from the participants. The statistical data analysis used a mixed logit model to predict the relative importance of the attributes. Results Most of the 65 patients interviewed were men (53.8%), mean age of 65 (95% confidence interval [CI]: 63–67) years and lung cancer stage IV (67.7%). Except for hospitalization and administration mode, the attributes coefficients were statistically significant (p < 0.005) for patients’ preferences. Patients would require a minimum survival gain of 11.72 (CI: 10.28–4.22) months and 19.72 (CI: 17.31‐7.09) months to accept a treatment that causes severe tiredness and severe skin rash, respectively. The market share of the treatments was calculated according to the DCE aggregate-level estimation, considering the impact of each treatment’s side effects. Paclitaxel plus carboplatin had an estimated market share of 31%, followed by gefitinib (27%), erlotinib (24%) and docetaxel (18%). Conclusion In general, less than a year of survival gain would not suffice for the appearance of severe skin rash or tiredness.
Description
Palavras-chave
Non-small-cell lung cancer, Patient Preference
Citação
Meirelles I, Magliano C. Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment. Patient Prefer Adherence. 2021;15:911-917. Doi:10.2147/PPA.S302394.